Abstract:Objective To determine the relation between body mass index (BMI) and liver cirrhosis and the contribution that BMI and alcohol consumption make to the incidence of liver cirrhosis in middle aged women in the UK. Design Prospective cohort study (Million Women Study). Setting Women recruited from 1996 to 2001 in NHS breast screening centres and followed by record linkage to routinely collected information on hospital admissions and deaths. Participants 1 230 662 women (mean age 56 years at recruitment) followed… Show more
“…[1][2][3][4] The liver is a key visceral organ that is affected by ectopic fat accumulation, 1,2 and when excess body weight is present, the incidence of cirrhosis is markedly increased. 5,6 When liver fat accumulation >5% occurs that is not caused by excessive alcohol consumption or other known pathogenic factors, the presence of liver fat defines nonalcoholic fatty liver disease (NAFLD).…”
Section: Please See Http://atvbahajournalsorg/site/misc/ Atvb_in_fomentioning
Ectopic fat accumulation in the liver causes nonalcoholic fatty liver disease (NAFLD), which is the most common cause of chronic liver disease in Western countries. Ectopic liver lipid, particularly diacylglycerol, exacerbates hepatic insulin resistance, promotes systemic inflammation, and increases risk of developing both type 2 diabetes mellitus and cardiovascular disease. Increasing evidence suggests that NAFLD is an emerging risk factor for cardiovascular disease, and although there are currently no licensed treatments for NAFLD per se, current evidence suggests that statin treatment is safe in NAFLD. Presently, there is insufficient evidence to indicate that statins or other cardioprotective agents, such as angiotensin receptor blockers, are effective in treating NAFLD. In this brief narrative review, we discuss the diagnosis of NAFLD and the role of ectopic liver fat to cause insulin resistance and to increase risk of both type 2 diabetes mellitus and cardiovascular disease. For this review, PubMed was searched for articles using the key words non-alcoholic fatty liver disease or fatty liver combined with diabetes risk, cardiovascular risk, and cardiovascular mortality between 1990 and 2014. Articles published in languages other than English were excluded.
“…[1][2][3][4] The liver is a key visceral organ that is affected by ectopic fat accumulation, 1,2 and when excess body weight is present, the incidence of cirrhosis is markedly increased. 5,6 When liver fat accumulation >5% occurs that is not caused by excessive alcohol consumption or other known pathogenic factors, the presence of liver fat defines nonalcoholic fatty liver disease (NAFLD).…”
Section: Please See Http://atvbahajournalsorg/site/misc/ Atvb_in_fomentioning
Ectopic fat accumulation in the liver causes nonalcoholic fatty liver disease (NAFLD), which is the most common cause of chronic liver disease in Western countries. Ectopic liver lipid, particularly diacylglycerol, exacerbates hepatic insulin resistance, promotes systemic inflammation, and increases risk of developing both type 2 diabetes mellitus and cardiovascular disease. Increasing evidence suggests that NAFLD is an emerging risk factor for cardiovascular disease, and although there are currently no licensed treatments for NAFLD per se, current evidence suggests that statin treatment is safe in NAFLD. Presently, there is insufficient evidence to indicate that statins or other cardioprotective agents, such as angiotensin receptor blockers, are effective in treating NAFLD. In this brief narrative review, we discuss the diagnosis of NAFLD and the role of ectopic liver fat to cause insulin resistance and to increase risk of both type 2 diabetes mellitus and cardiovascular disease. For this review, PubMed was searched for articles using the key words non-alcoholic fatty liver disease or fatty liver combined with diabetes risk, cardiovascular risk, and cardiovascular mortality between 1990 and 2014. Articles published in languages other than English were excluded.
“…Given that patients in HES-linked practices are representative of the whole CPRD population and the latter is broadly similar in terms of demographics to that of England, we believe we have a representative population ( 10,16 ). Our defi nition of cirrhosis in secondary care, compared with that used by other studies, which included codes for chronic hepatitis and alcoholic liver disease ( 4,17 ), ensures that we are only including patients who have good evidence of cirrhosis. Although we have assigned a diagnosis date as the incident date of disease in our study (so as to be able to calculate rates of occurrence from a defi ned denominator), we appreciate that given the long sojourn time for cirrhosis to develop this will not be the onset of disease.…”
There is no routine registration of the occurrence of newly diagnosed cases of cirrhosis in the United Kingdom. This study seeks to determine precise estimates and trends of the incidence of cirrhosis in England, and directly compare these fi gures with those for the 20 most commonly diagnosed cancers in the United Kingdom.
METHODS:We used the Clinical Practice Research Datalink and linked English Hospital Episode Statistics to perform a population-based cohort study. Adult incident cases with a diagnosis of cirrhosis between January 1998 and December 2009 were identifi ed. We described trends in incidence by sex and etiology. We performed a direct standardization to estimate the number of people being newly diagnosed with cirrhosis in 2009, and calculated the change in incidence between 1998 and 2009.
RESULTS:A total of 5,118 incident cases of cirrhosis were identifi ed, 57.9 % were male. Over the 12-year period, crude incidence increased by 50.6 % . Incidence increased for both men and women and all etiology types. We estimated approximately 17,000 people were newly diagnosed with cirrhosis in 2009 in the United Kingdom, greater than that of the fi fth most common cancer non-Hodgkin ' s lymphoma. The percentage change in incidence of cirrhosis between 1998 and 2009 for both men (52.4 % ) and women (38.3 % ) was greater than that seen for the top four most commonly diagnosed cancers in the United Kingdom (breast, lung, bowel, and prostate).
CONCLUSIONS:The occurrence of cirrhosis increased more than that of the top four cancers during 1998 to 2009 in England. Strategies to monitor and reduce the incidence of this disease are urgently needed.SUPPLEMENTARY MATERIAL is linked to the online version of the paper at
“…2,18,19 In brief, it is a prospective cohort study that recruited 1.3 million women (mean age, 56.1 years) between 1996 and 2001, through the National Health Service (NHS) Breast Screening Pro-gramme in England and Scotland. At recruitment, women completed a questionnaire that enquired about current weight and height, use of hormone replacement therapy, smoking status, physical activity, alcohol consumption, medical and reproductive history, history of oral contraceptive use, and educational attainment (questionnaire available from www.millionwomenstudy.org).…”
Section: Study Populationmentioning
confidence: 99%
“…22 Incidence rates for the complete cohort were subsequently reported with the mean measured values for each body mass index category by use of methods described previously. 19 Million Women Study participants were excluded from the present analysis if they reported a history of blood clots or treatment for clotting problems at recruitment; or if, before recruitment, they had a hospital admission for venous thromboembolism (see online-only Data Supplement Appendix for International Classifications of Diseases codes), had surgery in the previous 12 weeks, or had a previous cancer registration (excluding nonmelanoma skin cancer). Women were classified as having had surgery during follow-up if the hospital data included 1 or more Classification of Surgical Operations and Procedures of the Office of Population Censuses and Surveys, fourth revision, codes (other than those related to the diagnosis and treatment of venous thromboembolism and those identified as nonoperative procedures in NHS coding guidelines, 23 as listed in the online-only Data Supplement Appendix).…”
FRS, for the Million Women Study CollaboratorsBackground-Obesity and surgery are known risk factors for venous thromboembolism (VTE), but there is limited information about the independent effects of obesity on the incidence of postoperative VTE. We linked questionnaire data from the Million Women Study with hospital admission and death records to examine the risk of VTE in relation to body mass index (BMI) both in the absence of surgery and in the first 12 weeks following an operation. Methods and Results-Overall, 1 170 495 women (mean age, 56.1 years) recruited in 1996 to 2001 through the National Health Service Breast Screening Programme in England and Scotland were followed for an average of 6 years, during which time 6438 were admitted to hospital or died of VTE. The adjusted relative risks of VTE increased progressively with increasing BMI and women with a BMI Ն35 kg/m 2 were 3-4 times as likely to develop VTE as those with a BMI 22.5 to 24.9 (relative risk 3.45 [95% CI 3.09 -3.86]). Overweight and obese women were more likely than lean women to be admitted for surgery and also to develop postoperative VTE. During a 12-week period without surgery, the incidence rates of VTE per 1000 women with a BMI Ͻ25 and Ն25 were 0.10 (0.09 -0.10) and 0.19 (0.18 -0.20); the corresponding rates in the 12 weeks following day and inpatient surgery were, respectively, about 4 and 40 times higher. Conclusions-VTE risk increases with increasing BMI and the associated excess risk is much greater after surgery than without surgery. (Circulation. 2012;125:1897-1904.)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.